Detalhe da pesquisa
1.
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Cancer
; 130(3): 400-409, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864520
2.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Oncologist
; 29(4): e514-e525, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38297981
3.
Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets.
Cancers (Basel)
; 16(6)2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539474
4.
Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing.
J Immunother Precis Oncol
; 7(1): 7-17, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38327755
5.
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Cancer Res Commun
; 4(2): 378-387, 2024 02 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38126764
6.
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
Cancer Discov
; 14(5): 828-845, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38358339
7.
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.
NPJ Breast Cancer
; 9(1): 66, 2023 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37567892
8.
Discordance of HER2 Expression and/or Amplification on Repeat Testing.
Mol Cancer Ther
; 22(8): 976-984, 2023 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37339271
9.
Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.
J Immunother Precis Oncol
; 6(3): 158-161, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37637237
10.
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
Clin Cancer Res
; 29(21): 4385-4398, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279095
11.
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
J Clin Oncol
; 41(9): 1725-1734, 2023 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36469840
12.
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer.
J Immunother Precis Oncol
; 6(1): 10-18, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36751659
13.
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
Nat Med
; 29(1): 115-126, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36658425
14.
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Sci Rep
; 12(1): 8701, 2022 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35610322
15.
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
Front Oncol
; 12: 818679, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35372008
16.
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience.
J Adv Pract Oncol
; 13(7): 664-672, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36199491
17.
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.
Onco Targets Ther
; 14: 3037-3049, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33994796
18.
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
Clin Cancer Res
; 27(11): 3050-3060, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33771853
19.
Phase 2 study of pembrolizumab in patients with advanced rare cancers.
J Immunother Cancer
; 8(1)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32188704
20.
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Clin Cancer Res
; 25(7): 2033-2041, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442682